Patent ID: 7998943

Claim:
A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme Core 2 GIcNAc-T comprising administering to the subject a therapeutically effective amount of an inhibitor of core 2 GIcNAc-T of formula (III): wherein Z is a steroid moiety of the formula (VI): the group Z incorporating additional group (VIa) or (VIc): wherein: when the steroid group incorporates additional group (VIa): R 7 , R 12 , R 14 , R 15 and R 19 are independently selected from H and —OH; R 8 , R 11 and R 18 are —CH 3 ; R 9 , R 13 , R 16 and R 17 are H; R 10 is H or —OH or the H normally present is absent and R 10 is ═O; R 19 is H or —OH; R 20 is H, —OH or —OCH 3 or R 19 and R 20 taken together represent the second bond of a double bond joining adjacent carbon atoms; R 21 is selected from the group consisting of 3-methylenebutyl substituted at the 4-position by glucose, 4-hydroxy-3-methylbutanyl, 3-methylbutanyl substituted at the 4-position by glucose, 1-hydroxy-3-methylbutanyl substituted at the 4-position by glucose or 1-methoxy-3-methylbutanyl substituted at the 4-position by glucose; and represents either a single bond or a double bond; and wherein when the steroid group incorporates additional group (VIc): R 7 , R 12 , R 14 , R 15 and R 24 are independently selected from H and —OH; R 8 , R 11 and R 23 are —CH 3 ; R 9 , R 13 , R 16 and R 17 are H; R 10 is H or —OH or the H normally present is absent and R 10 is ═O; R 25 is —CH 3 , —CH 2 OH or ═CH 2 ; X is O or NH; and represents either a single bond or a double bond; or a pharmaceutically acceptable salt, ether or ester form thereof; and wherein the condition associated with detrimental activity of Core 2 GIcNAc-T is selected from the group consisting of: vascular diseases, autoimmune conditions, inflammatory conditions, Wiskott Aldrich syndrome and cancer metastasis.